Using a motorcycle rider behaviour questionnaire (MRBQ) to investigate the predictors of motorcyclists' crash risk

In 2005, there were over 23,000 motorcyclists (including moped riders) involved in injury road traffic crashes in Great Britain and 6,142 of these riders were killed or seriously injured (Department for Transport, 2006). In order to reduce the casualty rates it is necessary to understand why motorcycle crashes happen. The present study approached this issue by investigating the role of aberrant rider behaviour, using a Motorcycle Rider Behaviour Questionnaire (MRBQ) as a framework. The aims of the study were to test the reliability and discriminant validity of the MRBQ and to examine which MRBQ behaviours relate to crash risk. Following the Driver Behaviour Questionnaire (e.g., Reason et al., 1990), which classifies driver behaviour into a system of errors ('the failure of planned actions to achieve their intended consequences') and violations ('deliberate deviations from those practices necessary to maintain the safe operation of a potentially hazardous system'), the MRBQ measured errors and violations, but with regard to motorcycling rather than car driving (see Elliott, Baughan & Sexton, 2007). The questionnaire consisted of 43 items to measure the self-reported frequency of specific riding behaviours. The questionnaire was administered to a sample of motorcyclists via a postal survey (N = 8,666). Principal components analysis revealed a 5-factor solution (TRAFFIC ERRORS, CONTROL ERRORS, SPEED VIOLATIONS, performance of STUNTS, and use of SAFETY EQUIPMENT). Generalised linear modelling showed that, while controlling for the effects of age, experience and annual mileage, TRAFFIC ERRORS were the main predictors of crash risk. For crashes in which respondents accepted some degree of blame, CONTROL ERRORS and SPEED VIOLATIONS were also significant predictors of crash risk. Implications of the findings will be discussed in relation to deciding on which countermeasures may be most effective at reducing motorcycle casualty rates

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Drivers' Compliance with Speed Limits: An Application of the Theory of Planned Behavior

The theory of planned behavior (TPB; I. Ajzen, 1985) was applied to drivers' compliance with speed limits. Questionnaire data were collected for 598 drivers at 2 time points separated by 3 months. TPB variables,' demographic information, and self-reported prior behavior were measured at Time 1, and self-reported subsequent behavior was measured at Time 2. In line with the TPB, attitude, subjective norm, and perceived control were positively associated with behavioral intention, and intention and perceived control were positively associated with subsequent behavior. TPB variables mediated the effects of age and gender on behavior. Prior behavior was found to moderate the perceived control-intention and perceived control-subsequent behavior relationships. Practical implications of the findings for road safety and possible avenues for further research are discussed

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk

We performed a meta-analysis of five genome-wide association studies to identify common variants influencing colorectal cancer (CRC) risk comprising 8,682 cases and 9,649 controls. Replication analysis was performed in case-control sets totaling 21,096 cases and 19,555 controls. We identified three new CRC risk loci at 6p21 (rs1321311, near CDKN1A; P = 1.14 × 10 -10), 11q13.4 (rs3824999, intronic to POLD3; P = 3.65 × 10 -10) and Xp22.2 (rs5934683, near SHROOM2; P = 7.30 × 10 -10) This brings the number of independent loci associated with CRC risk to 20 and provides further insight into the genetic architecture of inherited susceptibility to CRC.</p

Preparation for commissioning of materials detritiation facility at Culham Science Centre

The Materials Detritiation Facility has been designed to thermally treat solid non-combustible radioactive waste produced during operations of the Joint European Torus (JET) that is classified as Intermediate Level Waste in the UK due to its tritium inventory (> 12 kBq/g). The waste will be thermally treated in a retort furnace at temperatures up to 1000 degrees C under a flowing air atmosphere to reduce its tritium inventory sufficiently to allow its disposal at a lower waste category via existing disposal routes. The gaseous flow from the furnace will be processed via a bubbler system, where released tritium will be trapped in water. Commissioning of the facility will be divided into two main parts: inactive and active. The main purpose of the inactive commissioning is to verify that all components and safety systems of the facility are installed, tested and operated properly and within their operational limits. Several trials of the furnace with non-radioactive materials will be performed to verify its temperature profile, and to verify operation of the gaseous process line. During the active commissioning, small amounts of tritium-contaminated material will be introduced into the facility and used for active trials. The tritium inventory in this material has been selected based on the As low as reasonably practicable (ALARP) principle, to ensure that the activity levels are sufficient to fully test the control instrumentation and pose minimal risk to operators during commissioning. Overall, four active trials will be performed with carbon-based and Inconel materials with total tritium inventories of 1MBq, 3GBq, 20GBq and 26GBq. Tritium levels in the bubblers as well as in aerial discharge from the facility will be monitored. Furthermore, all materials used in the active trials will be sampled and analyzed to verify the performance of the process and confirm that a major part of tritium inventory can be removed from materials by the process